Skip to main content
. 2018 Nov 21;8:532. doi: 10.3389/fonc.2018.00532

Figure 4.

Figure 4

Interaction between immunotherapy and PD-1/PD-L1 blockade in the TME. PD-1/PD-L1 blockade in combination with other co-inhibitory checkpoints, co-stimulatory checkpoints, or other immunotherapies such as tumor vaccines or oncolytic viruses may overcome the tumor resistance to PD-1/PD-L1, thereby enhancing the antitumor immune response.